SJS Investment Consulting’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$489K Buy
1,943
+153
+9% +$32.9K 0.05% 94
2026
Q1
$389K Sell
1,790
-384
-18% -$85.2K 0.05% 94
2025
Q4
$497K Buy
2,174
+12
+0.6% +$2.73K 0.06% 76
2025
Q3
$501K Buy
2,162
+606
+39% +$123K 0.07% 74
2025
Q2
$289K Sell
1,556
-941
-38% -$175K 0.05% 78
2025
Q1
$523K Buy
2,497
+901
+56% +$175K 0.09% 52
2024
Q4
$284K Sell
1,596
-35
-2% -$6.43K 0.05% 73
2024
Q3
$322K Sell
1,631
-8
-0.5% -$1.49K 0.06% 70
2024
Q2
$281K Hold
1,639
0.05% 69
2024
Q1
$298K Buy
1,639
+76
+5% +$13.1K 0.06% 68
2023
Q4
$242K Sell
1,563
-18
-1% -$2.62K 0.05% 75
2023
Q3
$236K Buy
1,581
+16
+1% +$2.35K 0.06% 66
2023
Q2
$211K Buy
1,565
+8
+0.5% +$1.17K 0.05% 73
2023
Q1
$248K Sell
1,557
-22
-1% -$3.36K 0.07% 63
2022
Q4
$255K Buy
1,579
+35
+2% +$5.37K 0.08% 64
2022
Q3
$207K Buy
+1,544
New +$222K 0.07% 73
2022
Q1
$242K Buy
1,494
+25
+2% +$3.63K 0.07% 79
2021
Q4
$199K Buy
+1,469
New +$174K 0.06% 88

Other funds holding ABBV

SJS Investment Consulting's ABBV Position: Q2 2026 in Review

SJS Investment Consulting increased its AbbVie (ABBV) stake by 8.5% in Q2 2026, buying an estimated $32.9K and bringing the position to 1,943 shares worth $489K. The position accounts for 0.05% of the portfolio, ranked #94.

SJS Investment Consulting first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. The position peaked at $523K in Q1 2025. 1,743 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • SJS Investment Consulting held 1,943 shares of AbbVie worth $489K as of Q2 2026.
  • SJS Investment Consulting bought 153 AbbVie shares in Q2 2026, an estimated $32.9K.
  • AbbVie made up 0.05% of SJS Investment Consulting's portfolio in Q2 2026, its #94 holding.
  • SJS Investment Consulting first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
  • SJS Investment Consulting's AbbVie position peaked at $523K in Q1 2025.
  • 1,743 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.